198 related articles for article (PubMed ID: 35703463)
1. Evaluation of Physicochemical Properties, Pharmacokinetics, Biodistribution, Toxicity, and Contrast-Enhanced Cancer MRI of a Cancer-Targeting Contrast Agent, MT218.
Li Y; Gao S; Jiang H; Ayat N; Laney V; Nicolescu C; Sun W; Tweedle MF; Lu ZR
Invest Radiol; 2022 Oct; 57(10):639-654. PubMed ID: 35703463
[TBL] [Abstract][Full Text] [Related]
2. Targeted Contrast Agents for Magnetic Resonance Molecular Imaging of Cancer.
Lu ZR; Laney V; Li Y
Acc Chem Res; 2022 Oct; 55(19):2833-2847. PubMed ID: 36121350
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Assessment of the Effectiveness of Magnetic Resonance Molecular Imaging of Extradomain-B Fibronectin for Detection and Characterization of Oral Cancer.
Hall RC; Ayat NR; Qiao PL; Vaidya AM; Ma D; Aminoshariae A; Stojanov I; Lu ZR
Mol Imaging Biol; 2020 Dec; 22(6):1532-1542. PubMed ID: 32789648
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Profile of Gadoquatrane: A Novel Tetrameric, Macrocyclic High Relaxivity Gadolinium-Based Contrast Agent.
Lohrke J; Berger M; Frenzel T; Hilger CS; Jost G; Panknin O; Bauser M; Ebert W; Pietsch H
Invest Radiol; 2022 Oct; 57(10):629-638. PubMed ID: 35703267
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and Tolerability of the Cancer-Targeting MRI Contrast Agent MT218 in Healthy Males.
Li Y; Apseloff G; Tweedle MF; Gao S; Henry E; Lu ZR
Invest Radiol; 2024 Feb; 59(2):165-169. PubMed ID: 38015107
[TBL] [Abstract][Full Text] [Related]
6. Effective MR Molecular Imaging of Triple Negative Breast Cancer With an EDB-Fibronectin-Specific Contrast Agent at Reduced Doses.
Ayat NR; Vaidya A; Yeung GA; Buford MN; Hall RC; Qiao PL; Yu X; Lu ZR
Front Oncol; 2019; 9():1351. PubMed ID: 31850230
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Safety Assessment of Gadopiclenol: A High-Relaxivity Macrocyclic Gadolinium-Based MRI Contrast Agent.
Gendron C; Bourrinet P; Dencausse A; Fretellier N
Invest Radiol; 2024 Feb; 59(2):108-123. PubMed ID: 37921752
[TBL] [Abstract][Full Text] [Related]
8. Nanotemplate-engineered nanoparticles containing gadolinium for magnetic resonance imaging of tumors.
Zhu D; Lu X; Hardy PA; Leggas M; Jay M
Invest Radiol; 2008 Feb; 43(2):129-40. PubMed ID: 18197065
[TBL] [Abstract][Full Text] [Related]
9. A novel gadolinium-based trimetasphere metallofullerene for application as a magnetic resonance imaging contrast agent.
Adiseshaiah P; Dellinger A; MacFarland D; Stern S; Dobrovolskaia M; Ileva L; Patri AK; Bernardo M; Brooks DB; Zhou Z; McNeil S; Kepley C
Invest Radiol; 2013 Nov; 48(11):745-54. PubMed ID: 23748228
[TBL] [Abstract][Full Text] [Related]
10. Noninvasive assessment and therapeutic monitoring of drug-resistant colorectal cancer by MR molecular imaging of extradomain-B fibronectin.
Vaidya A; Ayat N; Buford M; Wang H; Shankardass A; Zhao Y; Gilmore H; Wang Z; Lu ZR
Theranostics; 2020; 10(24):11127-11143. PubMed ID: 33042274
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and Assessment of Peptide Gd-DOTA Conjugates Targeting Extradomain B Fibronectin for Magnetic Resonance Molecular Imaging of Prostate Cancer.
Li Y; Han Z; Roelle S; DeSanto A; Sabatelle R; Schur R; Lu ZR
Mol Pharm; 2017 Nov; 14(11):3906-3915. PubMed ID: 28976766
[TBL] [Abstract][Full Text] [Related]
12. Magnetic Resonance Molecular Imaging of Extradomain B Fibronectin Improves Imaging of Pancreatic Cancer Tumor Xenografts.
Qiao P; Ayat NR; Vaidya A; Gao S; Sun W; Chou S; Han Z; Gilmore H; Winter JM; Lu ZR
Front Oncol; 2020; 10():586727. PubMed ID: 33194740
[TBL] [Abstract][Full Text] [Related]
13. Magnetic resonance molecular imaging of extradomain B fibronectin enables detection of pancreatic ductal adenocarcinoma metastasis.
Qiao PL; Gargesha M; Liu Y; Laney VEA; Hall RC; Vaidya AM; Gilmore H; Gawelek K; Scott BB; Roy D; Wilson DL; Lu ZR
Magn Reson Imaging; 2022 Feb; 86():37-45. PubMed ID: 34801672
[TBL] [Abstract][Full Text] [Related]
14. Physicochemical and Pharmacokinetic Profiles of Gadopiclenol: A New Macrocyclic Gadolinium Chelate With High T1 Relaxivity.
Robic C; Port M; Rousseaux O; Louguet S; Fretellier N; Catoen S; Factor C; Le Greneur S; Medina C; Bourrinet P; Raynal I; Idée JM; Corot C
Invest Radiol; 2019 Aug; 54(8):475-484. PubMed ID: 30973459
[TBL] [Abstract][Full Text] [Related]
15. Low-Molecular-Weight Iron Chelates May Be an Alternative to Gadolinium-based Contrast Agents for T1-weighted Contrast-enhanced MR Imaging.
Boehm-Sturm P; Haeckel A; Hauptmann R; Mueller S; Kuhl CK; Schellenberger EA
Radiology; 2018 Feb; 286(2):537-546. PubMed ID: 28880786
[TBL] [Abstract][Full Text] [Related]
16. Tumor Contrast Enhancement and Whole-Body Elimination of the Manganese-Based Magnetic Resonance Imaging Contrast Agent Mn-PyC3A.
Erstad DJ; Ramsay IA; Jordan VC; Sojoodi M; Fuchs BC; Tanabe KK; Caravan P; Gale EM
Invest Radiol; 2019 Nov; 54(11):697-703. PubMed ID: 31356382
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Targeted ECO/miR-200c Nanoparticles for Modulating Tumor Microenvironment and Treating Triple Negative Breast Cancer as Non-invasively Monitored by MR Molecular Imaging.
Schilb AL; Ayat NR; Vaidya AM; Hertz LM; Hall RC; Scheidt JH; Sun D; Sun Z; Gopalakrishnan R; Lu ZR
Pharm Res; 2021 Aug; 38(8):1405-1418. PubMed ID: 34389916
[TBL] [Abstract][Full Text] [Related]
18. Brain tumor enhancement in magnetic resonance imaging at 3 tesla: intraindividual comparison of two high relaxivity macromolecular contrast media with a standard extracellular gd-chelate in a rat brain tumor model.
Fries P; Runge VM; Bücker A; Schürholz H; Reith W; Robert P; Jackson C; Lanz T; Schneider G
Invest Radiol; 2009 Apr; 44(4):200-6. PubMed ID: 19300099
[TBL] [Abstract][Full Text] [Related]
19. A new polysaccharide macromolecular contrast agent for MR imaging: biodistribution and imaging characteristics.
Helbich TH; Gossman A; Mareski PA; Radüchel B; Roberts TP; Shames DM; Mühler M; Turetschek K; Brasch RC
J Magn Reson Imaging; 2000 Jun; 11(6):694-701. PubMed ID: 10862070
[TBL] [Abstract][Full Text] [Related]
20. Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent.
Harpur ES; Worah D; Hals PA; Holtz E; Furuhama K; Nomura H
Invest Radiol; 1993 Mar; 28 Suppl 1():S28-43. PubMed ID: 8486501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
